Lowering C-reactive protein with statins after an ischemic stroke avoids mortality and readmissions. A prospective cohort study

References

• Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.
   PubMed Web of Science ®Google Scholar
• Colhom HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis. Systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902–9.
   Google Scholar
• Biffi A, Devan WJ, Anderson CD, Cortellini L, Furie KL, Rosand J, et al. Statin treatment and functional outcome after ischemic stroke. Stroke. 2011;42:1314–19.
   PubMed Web of Science ®Google Scholar
• Elkind MS, Flint AC, Sciacca RR, Sacco RL. Lipid-lowering agent use at ischemic stroke onset. Neurology. 2005;65:253–8.
   PubMed Web of Science ®Google Scholar
• Martinez-Sanchez P, Rivera-Ordoñez C, Fuentes B, Ortega-Casarrubios MA, Idrovo L, Diez-Tejedor E. The beneficial effect of statins treatment by stroke subtype. Eur J Neurol. 2009;16:127–33.
   PubMed Web of Science ®Google Scholar
• Ní Chróinin D, Callaly EL, Duggan J, Merwick A, Hannon N, Sheehan O, et al. Association between acute statin therapy, survival and improved functional outcome after ischemic stroke. Stroke. 2011;42:1021–9.
   PubMed Web of Science ®Google Scholar
• Squizzato A, Romualdi E, Dentali F, Ageno W. Statins for acute ischemic stroke. Cochrane Database Syst Rev. 2011;(8):CD007551.
   Web of Science ®Google Scholar
• Cappellari M, De Luca C, Tinazzi M, Tomelleri G, Carletti M, Fiaschi A, et al. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study. J Neurol Sci. 2011;308:128–34.
   PubMed Web of Science ®Google Scholar
• Ní Chroinin D, Asplund K, Asberg S, Callaly E, Cuadrado-Godia E, Díez-Tejedor E, et al. Statin therapy and outcome after ischemic stroke. Systematic review and meta-analysis of observational studies and randomized trials. Stroke. 2013;44:448–56.
   Google Scholar
• Oliver MF. Cholesterol and strokes. Cholesterol lowering is indicated for strokes due to carotid atheroma. BMJ. 2000;320:459–60.
   Google Scholar
• Herbert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin agents, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:313–21.
   PubMed Web of Science ®Google Scholar
• Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 2006;66:232–45.
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-zocor trial. Circulation. 2006;114:281–8.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–8.
   PubMed Web of Science ®Google Scholar
• Arévalo-Lorido, Carretero-Gómez J, Calvo-Romero JM, Romero-Requena JM, Pérez-Alonso JL, Gutiérrez-Montaño C, et al.C-reactive protein in the acute phase of ischemic stroke. Med Clin (Barc). 2005;125: 766–9.
   PubMed Web of Science ®Google Scholar
• Arévalo-Lorido, Carretero-Gómez J. C-reactive protein and carotid intima-media thickness in atherothrombotic ischemic stroke. Med Clin (Barc). 2009;133:496–500.
   PubMed Web of Science ®Google Scholar
• Arévalo-Lorido, Carretero-Gómez J, Álvarez-Oliva A, Gutiérrez-Montaño C, Fernández-Recio JM, Najarro-Díez F. Mean platelet volume in acute phase of ischemic stroke, as predictor of mortality and functional outcome after 1 year. J Stroke Cerebrovasc Dis. 2013;22:297–303.
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
   Google Scholar
• Lyden PD, Lu M, Levine SR, Brott TG, Broderick J; NINDS rTPA Stroke Study Group.A modified National Institute of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. Stroke. 2001;32:1310–17.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
   PubMedGoogle Scholar
• Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-bind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245–51.
   Google Scholar
• Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomized controlled trials. BMJ. 2001;323:75–81.
   PubMed Web of Science ®Google Scholar
• Cantoni E, Ronchetti E. Robust inference for generalized linear models. J Am Stat Assoc. 2001;96:1022–30.
   Web of Science ®Google Scholar
• Goldstein LB, Amarenco P, Zivin J, Messiq M, Altafullah I, Callaham A, et al. Stroke prevention by aggressive reduction in cholesterol levels investigators. Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCLE) trial. Stroke. 2009;40:3526–31.
   Google Scholar
• Blanco M, Nombela F, Castellanos M, Rodríguez-Yañez M, García-Gil M, Leira R, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69:904–10.
   PubMed Web of Science ®Google Scholar
• Kennedy J, Hill MD, Rickburst KJ, Eliasziw M, Demchuk AM, Bucham AM; FASTER investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007;6:961–9.
   PubMed Web of Science ®Google Scholar
• Ovbviagele B, Saber JL, Starkman S, Kim D, Ali LK, Jahan R, et al. Statin enhancement of collateralization in acute stroke. Neurology. 2007;68:2129–31.
   PubMed Web of Science ®Google Scholar
• Chen P-S, Cheng C-L, Kao Yang Y-H, Yeh P-S, Li Y-H. Impact of early statin therapy in patients with ischemic stroke or transient ischemic attack. Acta Neurol Scand. 2014;129:41–8.
   PubMed Web of Science ®Google Scholar
• Miedema I, Ugttenboogaart M, Koopman K, De Keyser J, Luijck GC. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke. Cerebrovasc Dis. 2010;29: 263–7.
   PubMed Web of Science ®Google Scholar
• Engelter ST, Soinne L, Ringleb P, Sarikaya H, Burdet R, Berrouschot J, et al. IV thrombolysis and statins. Neurology. 2011;77:888–95.
   PubMed Web of Science ®Google Scholar
• Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, et al. Association of circulating inflammatory markers with recurrent vascular events after stroke: a prospective cohort study. Stroke. 2011;42:10–16.
   PubMed Web of Science ®Google Scholar
• Idicula TT, Brogger J, Naess H, Waje-Andreassen U, Thomassen L. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the “Bergen stroke Study”. BMC Neurol. 2009;9:18.
   PubMed Web of Science ®Google Scholar
• Samson Y, Lapergue B, Hosseini H. Inflammation and ischaemic stroke: current status and future perspectives. Rev Neurol [Paris]. 2005;165: 1177–82.
   Google Scholar
• Lefer DJ. Statins as potent antiinflammatory drugs. Circulation. 2002; 106:2041–2.
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members. Stroke. 2005;36:1316–29.
   PubMed Web of Science ®Google Scholar
• Martínez-Sanchez P, Fuentes B, Martínez-Martínez M, Ruiz-Ares G, Fernández-Travieso J, Sanz-Cuesta BE, et al. Treatment with statins and ischemic stroke severity: does the dose matter? Neurology. 2013;80: 1800–5.
   PubMed Web of Science ®Google Scholar